Page 89 - Read Online

Farrell et al. Hepatoma Res 2020;6:18 I http://dx.doi.org/10.20517/2394-5079.2019.019 Page 13 of 13

41. Calzadilla-Bertot L, Jeffrey GP, Jacques B, McCaughan G, Crawford M, et al. Increasing incidence of nonalcoholic steatohepatitis as an
indication for liver transplantation in Australia and New Zealand. Liver Transpl 2019;25:25-34.
42. Hong TP, Gow PJ, Fink M, Dev A, Roberts SK, et al. Surveillance improves survival of patients with hepatocellular carcinoma: a
prospective population-based study. Med J Aust 2018;209:348-54.
43. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on
systematic review. Clin Gastroenterol Hepatol 2012;10:1342-59.e2.
44. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, et al. The incidence and risk factors of hepatocellular carcinoma in patients
with nonalcoholic steatohepatitis. Hepatology 2010;51:1972-8.
45. Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis
or cirrhosis: an international collaborative study. Hepatology 2011;54:1208-16.
46. Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, et al. Clinical features and outcomes of cirrhosis due to non-alcoholic
steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 2009;24:248-54.
47. Sanyal AJ, Banas C, Sargeant C, Luketic VA, Sterling RK, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic
steatohepatitis and hepatitis C. Hepatology 2006;43:682-9.
48. Mohamad B, Shah V, Onyshchenko M, Elshamy M, Aucejo F, et al. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic
fatty liver disease (NAFLD) patients without cirrhosis. Hepatol Int 2016;10:632-9.
49. Piscaglia F, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marinelli S, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic
fatty liver disease: a multicenter prospective study. Hepatology 2016;63:827-38.
50. Ertle J, Dechêne A, Sowa JP, Penndorf V, Herzer K, et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the
absence of apparent cirrhosis. Int J Cancer 2011;128:2436-43.
51. Sadler EM, Mehta N, Bhat M, Ghanekar A, Greig PD, et al. Liver transplantation for NASH-related hepatocellular carcinoma versus non-
NASH etiologies of hepatocellular carcinoma. Transplantation 2018;102:640-47.
52. Bengtsson B, Stål P, Wahlin S, Björkström NK, Hagström H. Characteristics and outcome of hepatocellular carcinoma in patients with
NAFLD without cirrhosis. Liver Int 2019;39:1098-108.
53. Wang P, Kang D, Cao W, Wang Y, Liu Z. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis.
Diabetes Metab Res Rev 2012;28:109-22.
54. Chen Y, Wang X, Wang J, Yan Z, Luo J. Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective
studies. Eur J Cancer 2012;48:2137-45.
55. Yang JD, Mohamed HA, Cvinar JL, Gores GJ, Roberts LR, et al. Diabetes Mellitus Heightens the Risk of Hepatocellular Carcinoma
Except in Patients With Hepatitis C Cirrhosis. Am J Gastroenterol 2016;111:1573-80.
56. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, et al. Expanding the natural history of nonalcoholic steatohepatitis: from
cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-40.
57. Pischon T, Nimptsch K. Obesity and risk of cancer: an introductory overview. Recent Results Cancer Res 2016;208:1-15.
58. Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev
Gastroenterol Hepatol 2019;16:411-28.
59. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty
liver disease. Nat Genet 2008;40:1461-5.
60. Singal AG, Manjunath H, Yopp AC, Beg MS, Marrero JA, et al. The effect of PNPLA3 on fibrosis progression and development of
hepatocellular carcinoma: a meta-analysis. Am J Gastroenterol 2014;109:325-34.
61. Liu YL, Patman GL, Leathart JB, Piguet AC, Burt AD, et al. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased
risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol 2014;61:75-81.
62. Donati B, Dongiovanni P, Romeo S, Meroni M, McCain M, et al. MBOAT7 rs641738 variant and hepatocellular carcinoma in non-
cirrhotic individuals. Sci Rep 2017;7:4492.
63. Donati B, Pietrelli A, Pingitore P, Dongiovanni P, Caddeo A, et al. Telomerase reverse transcriptase germline mutations and hepatocellular
carcinoma in patients with nonalcoholic fatty liver disease. Cancer Med 2017;6:1930-40.
64. Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology
2015;149:1226-39.e4.
65. Zhang X, Liu S, Dong Q, Xin Y, Xuan S. The genetics of clinical liver diseases: insight into the TM6SF2 E167K variant. J Clin Transl
Hepatol 2018;6:326-31.
66. Liu YL, Reeves HL, Burt AD, Tiniakos D, McPherson S, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients
with non-alcoholic fatty liver disease. Nat Commun 2014;5:4309.
67. Taylor EJ, Jones RL, Guthrie JA, Rowe IA. Modeling the benefits and harms of surveillance for hepatocellular carcinoma: information to
support informed choices. Hepatology 2017;66:1546-55.
68. Cengiz M, Sentürk S, Cetin B, Bayrak AH, Bilek SU. Sonographic assessment of fatty liver: intraobserver and interobserver variability.
Int J Clin Exp Med 2014;7:5453-60.
69. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, et al. NAFLD may be a common underlying liver disease in patients with
hepatocellular carcinoma in the United States. Hepatology 2002;36:1349-54.
70. Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop
without significant liver fibrosis: a pathological analysis. Hepatology 2009;49:851-9.
71. Perumpail RB, Wong RJ, Ahmed A, Harrison SA. Hepatocellular carcinoma in the setting of non-cirrhotic nonalcoholic fatty liver disease
and the metabolic syndrome: US experience. Dig Dis Sci 2015;60:3142-8.